ArticleCancer medicine2019

DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia.

Guo-Kang Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.